AMH and hematologic disorder: Patients with hematological malignancies had significantly lower levels of serum AMH, with an estimated SMD of −0.62 (95% CI = −0.99 to −0.24, P = 0.001) and without heterogeneity (I2 = 0.0%, P = 0.452) (Table 2; Supplementary Fig. S4).